A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
Status:
Completed
Trial end date:
2018-04-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to
determine the maximum tolerated dose and recommended phase 2 dose of ASP4132. The study will
also determine the pharmacokinetics (PK) of ASP4132 and evaluate the preliminary antitumor
activity.